- Home
- EVAX
EVAX
Evaxion Biotech A/S
as 12-23-2024 10:37am EST
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 8.7M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 82.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $13.61 | Next Earning Date: | 10-31-2024 |
| Revenue: | $3,295,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4845.21% | Revenue Growth (next year): | 30.30% |
Latest Evaxion Biotech A/S News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
GlobeNewswire
11 days ago
Evaxion establishes new AI-derived precision cancer vaccine concept
GlobeNewswire
14 days ago
Evaxion announces 2025 milestones reflecting continued strong strategy execution
GlobeNewswire
21 days ago
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
GlobeNewswire
a month ago
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
Zacks Small Cap Research
a month ago
EVAX Racks up Positive Test Results
GlobeNewswire
a month ago
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
GlobeNewswire
2 months ago
Evaxion announces business update and third quarter 2024 financial results
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.